Pfizer Ends Development of Vupanorsen Over Disappointing Results, Safety Issues
Pfizer and Ionis Pharmaceuticals have decided to discontinue the clinical development program for vupanorsen (PF-07285557), an investigational antisense therapy that was being evaluated for potential indications in cardiovascular risk reduction and severe hypertriglyceridemia. The decision…